Meeting
2019 Gastrointestinal Cancers Symposium
Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
Authors
Mohamedtaki Abdulaziz Tejani
University of Rochester Medical Center, Rochester, NY
Mohamedtaki Abdulaziz Tejani , Eric Cheung , Peter D. Eisenberg , Aaron James Scott , Anteneh A. Tesfaye , Lyndah Dreiling , Clarence Eng , Neyssa Marina , Siddhartha Mitra , Hong Xiang , Xiaohong Yan , Daniel V.T. Catenacci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03343301
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 91)
DOI
10.1200/JCO.2019.37.4_suppl.91
Abstract #
91
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).
First Author: Zev A. Wainberg
Poster
2017 Gastrointestinal Cancers Symposium
A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.
First Author: James J. Harding
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.
First Author: Sun Young Rha